Vanguard Group’s EnteroMedics Inc. ETRM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-67,540
| Closed | -$119K | – | 4172 |
|
|
2017
Q3 | $119K | Buy |
67,540
+17,800
| +36% | +$52.5K | ﹤0.01% | 3976 |
|
|
2017
Q2 | $248K | Buy |
49,740
+9,727
| +24% | +$48.4K | ﹤0.01% | 3863 |
|
|
2017
Q1 | $230K | Buy |
40,013
+20,900
| +109% | +$155K | ﹤0.01% | 3885 |
|
|
2016
Q4 | $38K | Buy |
+19,113
| New | +$100K | ﹤0.01% | 4049 |
|
|
2016
Q3 | – | Sell |
-944
| Closed | -$19K | – | 4194 |
|
|
2016
Q2 | $19K | Sell |
944
-936
| -50% | -$42.9K | ﹤0.01% | 4118 |
|
|
2016
Q1 | $127K | Sell |
1,880
-725
| -28% | -$58.6K | ﹤0.01% | 4010 |
|
|
2015
Q4 | $356K | Sell |
2,605
-214
| -8% | -$44.4K | ﹤0.01% | 3901 |
|
|
2015
Q3 | $770K | Buy |
2,819
+976
| +53% | +$312K | ﹤0.01% | 3716 |
|
|
2015
Q2 | $1.2M | Buy |
1,843
+202
| +12% | +$232K | ﹤0.01% | 3609 |
|
|
2015
Q1 | $1.58M | Buy |
1,641
+52
| +3% | +$62.7K | ﹤0.01% | 3485 |
|
|
2014
Q4 | $2.37M | Buy |
1,589
+140
| +10% | +$189K | ﹤0.01% | 3227 |
|
|
2014
Q3 | $1.87M | Buy |
1,449
+182
| +14% | +$267K | ﹤0.01% | 3294 |
|
|
2014
Q2 | $2.08M | Buy |
1,267
+92
| +8% | +$172K | ﹤0.01% | 3250 |
|
|
2014
Q1 | $2.25M | Buy |
1,175
+280
| +31% | +$663K | ﹤0.01% | 3166 |
|
|
2013
Q4 | $1.92M | Buy |
895
+71
| +9% | +$114K | ﹤0.01% | 3198 |
|
|
2013
Q3 | $1.08M | Buy |
824
+23
| +3% | +$26.8K | ﹤0.01% | 3343 |
|
|
2013
Q2 | $959K | Buy |
+801
| New | +$846K | ﹤0.01% | 3320 |
|
Other funds holding ETRM
Vanguard Group's ETRM Position: Q4 2017 in Review
Vanguard Group sold out of EnteroMedics Inc. (ETRM) in Q4 2017, closing a stake of 67,540 shares — an estimated $119K sold.
Vanguard Group first reported a position in ETRM in Q2 2013 and held it in 17 quarters. The position peaked at $2.37M in Q4 2014. 1 fund tracked by Wall St. Rank holds ETRM as of Q4 2017.
- Vanguard Group reported no remaining EnteroMedics Inc. position as of Q4 2017 after selling out during the quarter.
- Vanguard Group sold 67,540 EnteroMedics Inc. shares in Q4 2017, an estimated $119K.
- Vanguard Group first reported a position in EnteroMedics Inc. in Q2 2013 and held it in 17 quarters.
- Vanguard Group's EnteroMedics Inc. position peaked at $2.37M in Q4 2014.
- 1 fund tracked by Wall St. Rank held EnteroMedics Inc. as of Q4 2017.
Based on Vanguard Group's 13F filing for Q4 2017, filed 14 Feb 2018.